Literature DB >> 11454467

Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.

F Kratz1, J Drevs, G Bing, C Stockmar, K Scheuermann, P Lazar, C Unger.   

Abstract

Two doxorubicin albumin conjugates (A-DP1 and A-DP2), which differ in their substrate specificity for the matrix metalloproteinases MMP2 and MMP9, were prepared by binding maleimide doxorubicin peptide derivatives to the cysteine-34 position of human serum albumin. The incorporated octapeptide, Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, in A-DP2 is not cleaved by activated MMP2 and MMP9 in contrast to Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln incorporated in A-DP1 that is cleaved efficiently by activated MMP2 and MMP9 liberating a doxorubicin tetrapeptide. A-DP1 showed antiproliferative activity in a murine renal cell carcinoma line in the low micromolar range (IC(50) value approximately 0.2 microM).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454467     DOI: 10.1016/s0960-894x(01)00354-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.

Authors:  Lin Zhu; Pooja Kate; Vladimir P Torchilin
Journal:  ACS Nano       Date:  2012-03-14       Impact factor: 15.881

Review 2.  Pharmaceutical strategies utilizing recombinant human serum albumin.

Authors:  Victor Tuan Giam Chuang; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

Review 3.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 4.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

5.  Evaluation of doxorubicin-loaded 3-helix micelles as nanocarriers.

Authors:  Nikhil Dube; Jessica Y Shu; He Dong; Jai W Seo; Elizabeth Ingham; Azadeh Kheirolomoom; Pin-Yuan Chen; John Forsayeth; Krystof Bankiewicz; Katherine W Ferrara; Ting Xu
Journal:  Biomacromolecules       Date:  2013-10-03       Impact factor: 6.988

6.  Matrix metalloproteinase-sensitive thermogelling polymer for bioresponsive local drug delivery.

Authors:  Vivek Kumar Garripelli; Jin-Ki Kim; Sejin Son; Won Jong Kim; Michael A Repka; Seongbong Jo
Journal:  Acta Biomater       Date:  2011-02-17       Impact factor: 8.947

7.  Functional analysis of recombinant human serum albumin domains for pharmaceutical applications.

Authors:  Sadaharu Matsushita; Yu Isima; Victor Tuan Giam Chuang; Hiroshi Watanabe; Sumio Tanase; Tomu Maruyama; Masaki Otagiri
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

Review 8.  Tumour endoproteases: the cutting edge of cancer drug delivery?

Authors:  J M Atkinson; C S Siller; J H Gill
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 9.  Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Authors:  Zhibo Liu; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-03-07       Impact factor: 54.564

10.  Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection.

Authors:  J Andrew MacKay; Mingnan Chen; Jonathan R McDaniel; Wenge Liu; Andrew J Simnick; Ashutosh Chilkoti
Journal:  Nat Mater       Date:  2009-11-08       Impact factor: 43.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.